Share

EORTC and Andaman7 are working together to develop Synchronized Health Records

Vincent Keunen (photo) runs the software development company that developed Andaman7, a collaborative electronic health record for doctors and patients. The multilingual Andaman7 app is a kind of mobile electronic health record system that can contain any medical record about the patient, entered by the patient, doctor, or through the hospital electronic health record system.

“I was enjoying a happy and healthy life with my family, when, in 2007, all hell broke loose. I got Leukemia, my ten year old son got bone cancer, and everything changed: priorities, dreams, objectives. This tough experience led to the creation of Andaman7. With this app, a patient can easily send my data to my doctor, to my specialist, to my sister, etc.”

Andaman7@eortc, a first project with EORTC, will enable data to be sent from patient > principal investigator > EORTC, if the patient agrees, and be useful for long term follow-up or even cancer survivorship projects.

appstore

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023